[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer---infiltrating-ductal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer---infiltrating-ductal-carcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100631914","phase-2-concurrent-neoadjuvant-chemoendocrine-therapy-in-her2-breast-cancer-100631914",false,"NCT07506876","Concurrent Neoadjuvant Chemo\u002FEndocrine Therapy in HER2+ Breast Cancer","Inclusion Criteria:\n\n1. Adults over 18 years of age with newly diagnosed, previously untreated, HR+, HER2+ breast cancer (positive per local guidelines)\n\n   1. Endocrine therapy for the current breast cancer may be started within 28 days prior to trial enrollment and must be initiated prior to C2 of chemotherapy\u002FHER2 directed therapy\n   2. Choice of endocrine therapy will be determined by the treating and\u002For enrolling physician\n2. Anatomic Stage IIA - IIIC breast cancer planning a minimum of 4 cycles of TCHP\n3. Patients must be Luminal A, Luminal B or HER2 enriched subtype on MammaPrint\u002FBluePrint performed on initial biopsy\n\nExclusion Criteria:\n\n1. Children under 18 years of age, pregnant women, prisoners, and decisionally impaired adults.\n2. Patients with non-breast cancer within prior 2 years\n3. Patients with breast cancer within prior 5 years\n4. Patients with recurrent breast cancer\n5. Patients with stage IV breast cancer","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery.\n\nThe purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery",[25,26],"Breast Cancer - Infiltrating Ductal Carcinoma","HER-2 Positive Breast Cancer","RECRUITING","2026-04-27",{"date":30,"type":31},"2026-05-01","ACTUAL",{"date":28,"type":31},{"date":34,"type":19},"2027-12",{"name":36,"class":37},"Legacy Health System","OTHER",4,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100608789","feasibility-study-for-the-sira-1000-sira-rfa-electrosurgical-device-as-an-adjunct-to-breast-conserving-surgery-100608789","NCT07206121","Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery","A Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery","Inclusion Criteria:\n\n1. Biologic female\n2. 50 years of age and older\n3. Confirmed diagnosis of breast cancer:\n\n   1. Infiltrating ductal carcinoma\n   2. ER\u002FPR+Her2neu-\n   3. Grade I, II, or III\n4. Unicentric, unilateral tumor size ≤ 3cm\n5. Tumor location ≥ 2 cm from skin and other structures\n6. Zubrod Performance Status of 0, 1, or 2\n7. No palpable lymphadenopathy\n8. Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. Neoadjuvant chemotherapy\n3. Cardiac arrhythmia\n4. Patients with active implantable medical devices, such as implanted cardiac pacemakers or defibrillators, or any other electronic device\n5. Current or history of breast implants\n6. Multi-centric or bilateral breast cancer\n7. Diffuse microcalcifications\n8. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter the outcomes under study\n9. Has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.","FEMALE","50 Years",{"count":49,"type":19},10,[51],"NA","This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.",[54,55,25,56,57],"Breast Cancer","Breast-conserving Surgery","ER\u002FPR+Her2neu","Grade I, II, III",[59],"Breast conserving surgery for breast cancer.","2026-02-09",{"date":62,"type":31},"2026-02-11",{"date":64,"type":19},"2026-02-10",{"date":66,"type":19},"2032-02-06",{"name":68,"class":69},"Innoblative Designs, Inc.","INDUSTRY",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":46,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":92,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":70},"100618429","validation-of-the-oncoliq-test-for-the-early-detection-of-breast-cancer-100618429","NCT07331506","Validation of the Oncoliq Test for the Early Detection of Breast Cancer.","Inclusion Criteria:\n\nGroup 1 - Breast Cancer:\n\nAge between 40 and 70 years Diagnosis of breast cancer at any stage No prior surgical treatment No prior antineoplastic treatment Pathology report available at the time of enrollment Signed informed consent\n\nGroup 2 - No Cancer (Control):\n\nAge between 50 and 70 years No diagnosis or personal history of any type of cancer Digital mammography and breast ultrasound showing no breast pathology (BI-RADS 1 or 2) Signed informed consent\n\nExclusion Criteria:\n\nRefusal to sign the informed consent Communication issues that hinder understanding (hearing loss, blindness, intellectual disability, or dementia) Venipuncture for blood collection impracticable or posing a risk Personal history of previous cancer",true,"40 Years","70 Years",{"count":81,"type":19},300,"OBSERVATIONAL","Cancer continues to be one of the most significant public health issues worldwide. Thanks to early detection, the mortality rate of certain types of cancer has decreased significantly. However, the lack of accessible, low-cost, non-invasive, non-toxic, and easy-to-implement diagnostic methods results in late diagnoses, leading to 1 in every 6 people dying from cancer today.\n\nMicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are found both inside cells and in bodily fluids such as blood and urine. Several studies have demonstrated their role in human diseases, especially cancer, where tumors release miRNAs into the bloodstream that can be used as biomarkers for early detection.\n\nThe research and development team at Oncoliq SAS identified a panel of miRNAs associated with breast cancer, with a detection performance of 82% sensitivity and 83% specificity, validated in exploratory and preliminary confirmatory studies. These results led to the filing of a patent based on liquid biopsy technology.\n\nThe objective of this protocol is to establish a panel of miRNAs for the early detection of breast cancer using samples from breast cancer patients and a cancer-free control group. Validation of the miRNAs will be carried out through RT-qPCR. This stage constitutes the analytical validation of the biomarkers, with the goal of developing an algorithm capable of classifying individuals with and without breast cancer. In future stages, a pilot clinical trial is planned to evaluate test implementation and clinical validation.",[85,86,87,88,25,89,90,91],"Breast Cancer Detection","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Breast Cancer Female","Breast Cancer - Ductal Carcinoma in Situ (DCIS)","Breast Cancer With Low to Intermediate HER2 Expression","Breast Cancer (Early Breast Cancer)","Breast Cancer - Female",[93,94,95,96],"Breast cancer","Detection","Liquid biopsy","miRNAs","2026-01-13",{"date":99,"type":31},"2026-01-15",{"date":101,"type":31},"2025-10-17",{"date":103,"type":19},"2026-02-28",{"name":105,"class":69},"Oncoliq US Inc"]